Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

[1]  G. Pond,et al.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer , 2020, European Journal of Cancer.

[2]  M. Aapro,et al.  BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Guadagni,et al.  Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials , 2019, Journal of bone oncology.

[4]  G. Hortobagyi,et al.  Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial , 2017, JAMA oncology.

[5]  P. Boland,et al.  Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. , 2017, The oncologist.

[6]  John D. Roberts,et al.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial , 2017, JAMA.

[7]  A. Shaywitz,et al.  Hypocalcaemia in patients with metastatic bone disease treated with denosumab. , 2015, European journal of cancer.

[8]  A. Gemma,et al.  A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  K. Kazuki,et al.  Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review. , 2014, Anticancer research.

[10]  K. Eguchi,et al.  Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13 , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Chow,et al.  Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  D. Amadori,et al.  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. , 2013, The Lancet. Oncology.

[14]  C. Bokemeyer,et al.  Reducing the burden of bone metastases , 2013, Supportive Care in Cancer.

[15]  G. Scagliotti,et al.  Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  G. Morgan,et al.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. , 2012, Blood.

[17]  H. Henk,et al.  Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid , 2012, Current Medical Research and Opinion.

[18]  M. Hameed,et al.  Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. , 2011, The Journal of bone and joint surgery. American volume.

[19]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[21]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Gralow,et al.  Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Fraser,et al.  Severe hypocalcaemia after being given intravenous bisphosphonate , 2004, BMJ : British Medical Journal.

[25]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[27]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[29]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.